Most companies don't know which capital paths are actually available to them. CAM measures readiness across fourteen, names the disqualifiers blocking access, and produces the work product to execute on the paths that fit.
At the lower middle market, CAM evaluates mezzanine structures from Audax, Twin Brook, Maranon, and seven other anchor lenders. At the upper middle market, it evaluates Q-of-E readiness against actual Big-Four standards. Every methodology reference is named, sourced, and verifiable.
Slot reserved · free capital mini-assessment button drops in here when readyFour moments most companies recognize. Not edge cases — the most common patterns in capital decisions across the operating-company revenue spectrum.
A $4M services company explores venture capital it cannot get because the business model doesn't fit what venture funds; nine months later, the founder accepts an SBA 7(a) loan that should have been the path from day one.
An $18M manufacturer accepts the first conventional bank term sheet because they don't know which covenant structures are negotiable; eighteen months later, a routine working-capital draw triggers a springing FCCR they didn't realize they'd signed.
A $40M company accepts a sponsor-backed minority recapitalization with a right-of-first-refusal clause that gives the sponsor the right to lead the eventual majority transaction; the founder discovers four years later that the recap was structurally a control transaction with delayed timing.
An $80M sponsor-owned business renegotiates a unitranche facility on covenant-lite terms for the lower headline rate; the CFO doesn't model that covenant-lite eliminates the maintenance covenant entirely, changing the lender-borrower power balance for the next five years.
The result is not always wrong, but it's consistently incomplete. The best-fit paths often don't make the consideration set. The disqualifiers that would kill a path at the underwriting committee don't surface until weeks into the application. The covenant package that should have been negotiated harder isn't, because the team didn't know what was negotiable. CAM exists to close that gap — calibrated to the company's stage and the decision-maker's role.
Fulcrum earns no fees from lenders or investors and maintains no referral relationships that compensate placement. Independent in the structural sense, not the marketing-language sense.
CAM does not pair companies with capital providers. The Source-of-Capital Pipeline identifies categories and, at upper tiers, anchor firms — what to look for and how to approach — but the company owns the relationship.
No platform, no algorithmic matching, no transaction take-rate. CAM is a diagnostic and an execution kit, not a transaction facilitator.
The diagnostic surfaces the structural gaps that block real eligibility, but closing those gaps is the company's work. CAM produces the plan; execution is what comes after.
CAM is also not a substitute for legal, accounting, or transaction-specific advisory counsel. The diagnostic informs the company's decisions; specific transactions still require the appropriate professional advisors.
Every question cites specific frameworks, named research, or specific transaction mechanics — not vague best practices. Every rubric anchor describes an observable behavior or measurable state, not a positive adjective. Every path module references actual lenders, actual covenant structures, actual diligence requirements practitioners recognize.
Specificity is the standard. Vagueness is the failure mode.
The methodology is anchored in published research from the people who built the relevant fields — Damodaran on revenue fragility and Treadmill Ratio mechanics, Warrillow on Value Builder methodology, and the substantive capital-markets literature on covenant structures, underwriting standards, and lender-borrower power dynamics. A CAM engagement is built to be defensible to the senior people in the company's life — the CFO, the board, the attorney, the senior banker, the M&A advisor — when they read the work product. That standard is non-negotiable.
The diagnostic asks structured questions across five dimensions. Each question maps to specific underwriting standards used by actual lenders — not generic best practices.
Books-quality, monthly close discipline, audit posture, working-capital management, and the specific signals lenders and equity providers use to assess whether financials survive sophisticated diligence.
Ownership structure, equity issuance history, vesting schedules, prior-round terms, and the structural cleanliness institutional investors and sophisticated lenders require before engaging.
Why this capital, why now, why this path, what it produces, what it costs, what alternatives were considered. Underwriters evaluate narrative quality before they evaluate financials.
Revenue predictability, customer concentration, contracted forward revenue, recurring-vs-transactional mix, and the operational signals that determine which capital structures match the model.
Data-room maturity, Quality-of-Earnings readiness, environmental and legal posture, governance documentation, and the gaps that delay or kill institutional transactions.
Active across all stages
Lower middle market and above
Upper middle market and above
CAM identifies which capital archetype the company fits — a structural classification, not a personality assessment. A Bootstrapped-To-Optionality company makes different decisions than a Disciplined Debt-Funded Growth company; an Institutional-Capital-Ready operator at $35M makes different decisions than a Sponsor-Owned company at $75M evaluating a recap. The archetype anchors the entire path-recommendation logic and the execution sequencing.
The diagnostic: the readiness scoring across all five dimensions, the archetype identification with its structural implications, and the path-by-path eligibility read — written to the same specificity as the questions that produced it. The document the leadership team walks a lender, sponsor, or board through.
A cross-path comparison rating each viable path on fit, eligibility, cost, control implications, and covenant structure — so the decision-maker can weigh the paths side by side rather than one at a time.
A sequenced plan — 90 to 360 days depending on tier — naming the specific gaps to close, the order, the owner, and the milestones that move the company from where it is to eligible on the paths that fit.
Categorical at lower tiers; named anchor firms at upper tiers — what to look for and how to approach. The company owns the relationship; Fulcrum takes no placement compensation.
The operational package, 80–350 pages depending on tier — the templates, checklists, and path-specific working documents that turn the plan into execution.
Working sessions with a Fulcrum partner — three at the lower tiers, scaling to eight to ten at institutional scale.
Each tier activates the path modules that are real at that stage, engages the archetype that fits, and scales the deliverable footprint. The engagement fee is disclosed in the discovery conversation.
The capital diagnostic at the lower middle market. SBA disappears; conventional bank gets sophisticated; mezzanine, unitranche, second-lien, minority growth equity, sponsor-backed minority recap, and institutional ESOP enter the picture. For teams evaluating the sponsor economy — or institutional alternatives to it — for the first time.
The capital diagnostic in sponsor territory. Unitranche dominant; covenant-lite structures real; second-lien meaningful; high-yield relevant at the upper end; strategic acquisition a credible path. For teams optimizing across an existing or imminent sponsor relationship — or evaluating paths that preserve independence.
The capital diagnostic at upper middle market and large-cap scale. Public-market readiness as a real diagnostic dimension; investment-grade debt for best-credit issuers; strategic M&A at full institutional standard; IPO readiness as structural assessment. For decisions with board-level and institutional-investor consequence.
CAM also runs at earlier stages, where SBA 7(a), conventional bank, and the foundational paths are the live decisions. The right tier is matched in the discovery conversation.
CAM comes from Fulcrum & Co. — the diagnostic practice of Ryan Erickson, who built and exited two companies, ran a 275-person organization through a revenue doubling, and has worked with 20+ founder-CEOs from pre-revenue through $800M+. It's the same practice whose leadership diagnostic took a SaaS company stalled at $50M for three years to $800M — and a trajectory toward $1.7B this year — by measuring the constraint its revenue chart was hiding. CAM applies that discipline to the capital decision: independent of any lender or investor, scored, and built to be defensible to the lender, sponsor, or board who reads it.
Every CAM engagement begins with a discovery conversation — a structured 30-minute call that surfaces the company's revenue stage, the decision-maker's current capital question, and the right tier. It works equally for the founder evaluating first capital decisions, the CEO weighing a refinancing, the CFO scoping a recapitalization, or the board evaluating strategic alternatives.
Pricing is scoped at engagement signing, calibrated to the appropriate tier and to whether CAM is engaged standalone or bundled with a Fulcrum leadership diagnostic; bundled engagements receive a structural discount at the firm's discretion. Engagement begins fourteen business days after the signed agreement, with the specific start date set at signing — the window allows preparation of the data room, scheduling of working sessions, and pre-engagement intake.
A CAM engagement is a significant decision, and the right buyer is often ready in two months, or six. The CAM Methodology Overview covers the diagnostic architecture, the five dimensions, the fourteen path modules, the archetype framework, and the discipline standard CAM is built to. Twelve pages, no email required.
Slot reserved · methodology-overview download link drops in hereAdvisors and boutique banks generally work on engagement letters tied to specific transactions, often with success fees, and typically engage companies that already know which path they're pursuing. CAM is an independent diagnostic that runs before the path decision — no transactional fee structure, no placement compensation, no commitment to any path. It produces the work product that informs which advisor or banker to engage, and at what tier of capital sophistication.
The leadership diagnostic measures operational and leadership architecture — execution, founder or CEO dependency, cultural coherence, talent fragility. CAM measures capital readiness — financial hygiene, cap-table clarity, diligence readiness, and path-by-path eligibility. Complementary products from the same firm; many companies engage both, and the bundled engagement integrates the work product at a structural discount.
Fourteen business days after the signed agreement. The window allows preparation of the data room, scheduling of working sessions, and pre-engagement intake structuring. The specific start date is set at signing.
A structured intake of roughly fifty-five financial and personal fields, plus documents: three years of business tax returns, three years of personal returns (for 20%+ owners), interim financials, current cap table, and existing capital-structure documentation. The intake is calibrated to engagement tier — upper-tier engagements include audit reports, board materials, and additional institutional documentation.
Yes. Every engagement operates under a mutual NDA executed at signing, and the work product belongs to the engaging company. Fulcrum maintains rigorous information security across the engagement.
The current CAM addresses capital being raised by the company. A separate sell-side diagnostic — exit, sale, or recapitalization decisions — is in development and engages on a separate basis. Companies evaluating sell-side decisions should raise it in the discovery conversation; CAM may still be the right starting point depending on the question.
Whoever owns the capital decision. At early stages, the founder-CEO; at growth stages, the CFO or VP Finance often joins; at the lower middle market and above, typically the CEO, CFO, and often the board chair or a designated member. The diagnostic is calibrated to the decision-maker's role, not to a single archetype of company.
The work product that informs those decisions is not the place to economize. A discovery conversation is the place to start. Fulcrum & Co. — we measure what no one else measures.
